Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial
Open accessThe DOI matches its Crossref record; 36 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This study explored neoplasm risk with liraglutide versus placebo in the LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) cohort. RESEARCH DESIGN AND METHODS: LEADER (NCT01179048) was an international, phase 3b, randomized, double-blind, controlled trial. Participants aged ≥50 years with type 2 diabetes and high cardiovascular risk were assigned 1:1 to receive liraglutide (≤1.8 mg daily; n = 4,668) or placebo (n = 4,672) in addition to standard care and monitored for 3.5–5 years (median follow-up 3.8 years). The occurrence of neoplasms was a prespecified, exploratory secondary end point. Post hoc analyses of the time to the first confirmed neoplasms were conducted using a Cox regression model. RESULTS: Neoplasm was confirmed in 10.1% of patients with liraglutide versus 9.0% with placebo (hazard ratio [HR] 1.12 [95% CI 0.99; 1.28]). The HR (95% CI) for liraglutide versus placebo was 1.06 (0.90; 1.25) for malignant neoplasms and 1.16 (0.93; 1.44) for benign neoplasms. Sensitivity analyses excluding neoplasms occurring <1 year or <2 years after randomization and analyses by sex provided similar results. In our main analyses, the 95% CI for the HR included one for all malignant neoplasms evaluated (including pancreatic and thyroid neoplasms) except for prostate neoplasms, which occurred in fewer liraglutide-treated patients. CONCLUSIONS: LEADER was not primarily designed to assess neoplasm risk. Firm conclusions cannot be made regarding numeric imbalances observed for individual neoplasm types (e.g., pancreatic cancer) that occurred infrequently. LEADER data do, however, exclude a major increase in the risk of total malignant neoplasms with liraglutide versus placebo. Additional studies are needed to assess longer-term exposure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among ∼4660 patients randomized to each group and followed for a median of 3.8 years, 5 patients in the liraglutide group and 3 patients in the placebo group received a thyroid cancer diagnosis (HR = 1.66 [CI 0.4–6.95]).33”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In fact, some studies exclude thyroid cases that are diagnosed too soon after drug exposure (e.g., <1 year). This consideration of a latency period can provide insight when distinguishing between a new diagnosis of preexisting thyroid cancer versus thyroid cancer carcinogenesis.33,38”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [33]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Overall, 10.1% of patients in the liraglutide group versus 9.0% in the placebo group had a neoplasm diagnosis (HR = 1.12 [CI 0.99–1.28]).”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [33]
The cited source says what the claim attributes to it.
In the citing paper
“The potential trophic and carcinogenic effects of GLP-1 RA have been investigated across a series of primary sites, including thyroid and pancreatic cancer, with inconsistent results.29,33,34”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [33]
The cited source says what the claim attributes to it.
In the citing paper
“RCT that evaluated the efficacy of GLP-1 RAs in individuals with diabetes or obesity have not shown a significantly increased risk of thyroid cancer.33,55,56”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [33]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“Glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1RAs) improve glycemic control with a low risk of hypoglycemia in people with type 2 diabetes (6).”
BackgroundSelf-citationBiology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 2×
“receptor expression has been reported in a wide range of rodent and human tissues, including the pancreatic islets, lung, heart, kidney, gastrointestinal tract, pituitary, skin, and several regions of the nervous system (7,8).”
BackgroundDistant metastasis occurs late during the genetic evolution of pancreatic cancer
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R. H., Eshleman, J. R., Nowak, M. A., et al. (2010) · Nature · doi:10.1038/nature09515 · Cited by 2,502 · cited 1×
“development of clinically evident pancreatic cancer is a process that takes many years (30).”
BackgroundLixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · cited 1×
“Theprimary reports for ELIXA andEXSCEL did not include data specific to skin neoplasms (31,32).”
BackgroundEffects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162 · cited 1×
“Theprimary reports for ELIXA andEXSCEL did not include data specific to skin neoplasms (31,32).”
BackgroundSelf-citationVilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944 · cited 2×
“criticism on methodological grounds, suggested an increased risk for pancreatic tumors with incretin-based therapy (18,20,21), a recent large, international registry study did not confirm an increased risk of pancreatic cancer versus sulfonylureas (median follow-up 1.”
BackgroundPyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014) · Endocrinology · doi:10.1210/en.2013-1934 · Cited by 876 · cited 2×
“receptor expression has been reported in a wide range of rodent and human tissues, including the pancreatic islets, lung, heart, kidney, gastrointestinal tract, pituitary, skin, and several regions of the nervous system (7,8).”
Background
Cited by
Rosenstock, J., Perkovic, V., Johansen, O. E., Cooper, M. E., Kahn, S. E., Marx, N., Alexander, J. H., Pencina, M., Toto, R. D., Wanner, C., et al. (2019) · JAMA · doi:10.1001/jama.2018.18269 · Cited by 1,084
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Tak, Y. J., & Lee, S. Y. (2021) · Current Obesity Reports · doi:10.1007/s13679-020-00422-w · Cited by 343
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer
Bezin, J., Gouverneur, A., Pénichon, M., Mathieu, C., Garrel, R., Hillaire-Buys, D., Pariente, A., & Faillie, J.-L. (2023) · Diabetes Care · doi:10.2337/dc22-1148 · Cited by 320
Pharmacotherapy of obesity: available medications and drugs under investigation.
Pilitsi, E., Farr, O. M., Polyzos, S. A., Perakakis, N., Nolen-Doerr, E., Papathanasiou, A.-E., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2018.10.010 · Cited by 248
Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review
Tak, Y. J., & Lee, S. Y. (2021) · The World Journal of Men's Health · doi:10.5534/wjmh.200010 · Cited by 184
Abd El Aziz, M., Cahyadi, O., Meier, J. J., Schmidt, W. E., & Nauck, M. A. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13924 · Cited by 160
“Regarding acute pancreatitis, pancreatic cancer and any malignant neoplasm as the main outcomes, the numbers of cases reported and the patient-years of observation in each arm were extracted from the main manuscripts reporting cardiovascular outcomes (including online supplementary material) or from specific reports a…”
Self-citationGLP1 Receptor Agonists—Effects beyond Obesity and Diabetes
Wilbon, S. S., & Kolonin, M. G. (2023) · Cells · doi:10.3390/cells13010065 · Cited by 101
Zong, X., Zhang, H., Zhu, L., Deehan, E. C., Fu, J., Wang, Y., & Jin, M. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2023.08.003 · Cited by 114
“Accumulating evidence suggests that obesity is associated with a dysregulated metabolic and immune system, which underlies the development of numerous obesity-associated comorbidities, including type II diabetes, non-alcoholic fatty liver disease, cardiovascular disease, and select cancers [2].”
BackgroundDiabetes and pancreatic cancer: Exploring the two-way traffic
Roy, A., Sahoo, J., Kamalanathan, S., Naik, D., Mohan, P., & Kalayarasan, R. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i30.4939 · Cited by 118
Wang, J., & Kim, C. H. (2022) · Endocrine Research · doi:10.1080/07435800.2021.1955255 · Cited by 74
“88]) was observed in the liraglutide group compared with placebo.(27) Consistent with preclinical and clinical trial findings, we showed that the risk of prostate cancer was lower in both Explorys and FDA FAERS databases.”
ResultBea, S., Son, H., Bae, J. H., Cho, S. W., Shin, J., & Cho, Y. M. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15292 · Cited by 64
“10 In the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial, 8 the frequency of thyroid cancer was similar in the liraglutide and placebo groups, while medullary thyroid cancer (MTC) was observed in only one patient from the placebo group.”
BackgroundResultInfluentialGLP-1RA Use and Thyroid Cancer Risk
Brito, J. P., Herrin, J. S., SWARNA, K. S., Ospina, N. S., Montori, V. M., Toro-Tobón, D., Umpierrez, G. E., Galindo, R. J., Deng, Y., Mickelson, M. M., et al. (2025) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2024.4852 · Cited by 76
Abrahami, D., Douros, A., Yin, H., Yu, O. H., Faillie, J.-L., Montastruc, F., Platt, R. W., Bouganim, N., & Azoulay, L. (2018) · BMJ · doi:10.1136/bmj.k4880 · Cited by 63
Wang, Z., Tu, Z., Xie, X., Cui, H., Kong, K. W., & Zhang, L. (2021) · Foods · doi:10.3390/foods10020315 · Cited by 68
“Recent studies reported that diabetes could contribute to the development of cancer via inflammation, and thus has been identified as a risk factor for cancer and cancer-related mortality [36,37].”
BackgroundDrugs for Non-alcoholic Steatohepatitis (NASH): Quest for the Holy Grail
Sharma, M., Premkumar, M., Kulkarni, A. V., Kumar, P., Reddy, D. N., & Rao, N. P. (2020) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2020.00055 · Cited by 61
“[99] Nauck MA, Jensen TJ, Rosenkilde C, Calanna S, Buse JB.”
BackgroundMedications for the treatment of obesity in adolescents
Woodard, K., Louque, L., & Hsia, D. S. (2020) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820918789 · Cited by 53
Putting GLP-1 RAs and Thyroid Cancer in Context: Additional Evidence and Remaining Doubts
Thompson, C. A., & Stürmer, T. (2023) · Diabetes Care · doi:10.2337/dci22-0052 · Cited by 51
Hamed, K. M., Alosaimi, M. N., Ali, B. A., Alghamdi, A. M., Alkhashi, T., Alkhaldi, S. S., Altowarqi, N. A., Alzahrani, H., Alshehri, A., Alkhaldi, R. K., et al. (2024) · Cureus · doi:10.7759/cureus.68390 · Cited by 94
“However, clinical research in humans has not shown any evidence of a higher risk [81].”
BackgroundCui, H., Wang, Y., Yang, S., He, G., Jiang, Z., Gang, X., & Wang, G. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106094 · Cited by 51
Vekić, J., Zeljković, A., Stefanović, A., Giglio, R. V., Ciaccio, M., & Rizzo, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212409 · Cited by 56
Mali, G., Ahuja, V., & Dubey, K. (2021) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13259 · Cited by 44
“[22] 2018 Randomized, double-blind, controlled trial Liraglutide (n = 4668) Placebo (n = 4672) 3.”
Patoulias, D., Doumas, M. N., Kotsis, V., Stavropoulos, K., Imprialos, K. P., Zografou, I., Petidis, K., Bakatselos, S., & Karagiannis, A. I. (2020) · Current Diabetes Reviews · doi:10.2174/1573399815666190614141918 · Cited by 53
Saengboonmee, C., Seubwai, W., Lert-itthiporn, W., Sanlung, T., & Wongkham, S. (2020) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2020.09.008 · Cited by 48
Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?
Lisco, G., De Tullio, A., Disoteo, O., Piazzolla, G., Guastamacchia, E., Sabbà, C., De Geronimo, V., Papini, E., & Triggiani, V. (2023) · Endocrine Connections · doi:10.1530/ec-23-0257 · Cited by 37
Shigeoka, T., Nomiyama, T., Kawanami, T., Hamaguchi, Y., Horikawa, T., Tanaka, T., Irie, S., Motonaga, R., Hamanoue, N., Tanabe, M., et al. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13247 · Cited by 39
Brown, J. C., Carson, T. L., Thompson, H. J., & Agurs‐Collins, T. (2021) · Obesity · doi:10.1002/oby.23161 · Cited by 45
“An important limitation is that these trials were not designed to assess cancer risk, and definitive conclusions cannot be made (80).”
BackgroundGlucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review
Espinosa De Ycaza, A. E., Brito, J. P., McCoy, R. G., Shao, H., & Singh Ospina, N. (2024) · Thyroid · doi:10.1089/thy.2023.0530 · Cited by 37
“33,55,56 Table 2 summarizes 5 meta-analyses of RCTs evaluating the association between GLP-1 RA and thyroid cancer.”
Skriver, C., Friis, S., Knudsen, L. B., Catarig, A., Clark, A. J., Dehlendorff, C., & Mørch, L. S. (2023) · Diabetologia · doi:10.1007/s00125-023-05972-x · Cited by 38
Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study
Ueda, P., Wintzell, V., Melbye, M., Eliasson, B., Svensson, A.-M., Franzén, S., Gudbjörnsdottir, S., Hveem, K., Jonasson, C., Svanström, H., et al. (2021) · Diabetologia · doi:10.1007/s00125-021-05508-1 · Cited by 31
The Influence of Anti-Diabetic Drugs on Prostate Cancer
Knura, M., Garczorz, W., Borek, A., Drzymała, F., Rachwał, K., George, K., & Francuz, T. (2021) · Cancers · doi:10.3390/cancers13081827 · Cited by 37
Incretin-Based Drugs and the Incidence of Prostate Cancer Among Patients With Type 2 Diabetes
Lu, S., Yin, H., Yu, O. H. Y., & Azoulay, L. (2022) · Epidemiology · doi:10.1097/ede.0000000000001486 · Cited by 34
Approach to the patient with thyroid nodules: considering GLP-1 receptor agonists
Kelly, C. A., & Sipos, J. A. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae722 · Cited by 30
Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists
Madsbad, S., & Holst, J. J. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac112 · Cited by 39
Kim, M., Kim, S. C., Kim, J., & Kim, B. H. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0105 · Cited by 26
Sharma, N., Khatib, M. N., Balaraman, A. K., Roopashree, R., Kaur, M., Srivastava, M., Barwal, A., Prasad, G. V. S., Rajput, P., Syed, R., et al. (2024) · International Urology and Nephrology · doi:10.1007/s11255-024-04266-4 · Cited by 21
Pantazopoulos, D., Gouveri, E., Papi, M., Papazoglou, D., & Παπάνας, Ν. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03257-w · Cited by 26
“Specific concerns regarding a potential association with skin cancer emerged from the Lira-glutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial [81], a large cardiovascular outcome trial of liraglutide.”
Ruze, R., Chen, Y., Xu, R., Song, J., Yin, X., Wang, C., & Xu, Q. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188844 · Cited by 23
Long-term cancer risk in users of GLP-1 agonists in Denmark: a nationwide emulated trial
Gamborg, M., Grand, M. K., Grell, K., Rosthøj, S., Pedersen‐Bjergaard, U., Torp-Pedersen, C. T., & Mørch, L. S. (2025) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2025.101346 · Cited by 32
Novel Treatments for Obesity: Implications for Cancer Prevention and Treatment
Cuttica, C. M., Briata, I. M., & DeCensi, A. (2023) · Nutrients · doi:10.3390/nu15173737 · Cited by 18
De Fano, M., Malara, M., Vermigli, C., & Murdolo, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168650 · Cited by 17
Patient initiation and maintenance of GLP-1 RAs for treatment of obesity
Patel, D., & Smith, A. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1947796 · Cited by 16
Khunti, K., Almalki, M., Chan, J. C. N., & Amod, A. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01458-6 · Cited by 19
Tanaka, Y., Iwaya, C., Kawanami, T., Hamaguchi, Y., Horikawa, T., Shigeoka, T., Yanase, T., Kawanami, D., & Nomiyama, T. (2021) · Diabetology International · doi:10.1007/s13340-021-00560-z · Cited by 18
“Interestingly, a recent clinical study reported that T2DM patients treated with DPP-4 inhibitors have decreased risks of breast cancer compared with treatment by metformin [24] or patients treated without DPP-4 inhibitors [25].”
InfluentialPradhan, R., Yu, O. H. Y., Platt, R. W., & Azoulay, L. (2023) · Diabetic Medicine · doi:10.1111/dme.15248 · Cited by 19
“Third, we assessed whether the association varies by GLP-1 RA type, liraglutide (a commonly used GLP-1 RA, with which a signal regarding skin cancer was found in the LEADER trial 3,5 ), and other GLP-1 RAs.”
Obesity-related gut hormones and cancer: novel insight into the pathophysiology
Guzzardi, M. A., Pugliese, G., Bottiglieri, F., Pelosini, C., Muscogiuri, G., Barrea, L., Savastano, S., & Colao, A. (2021) · International Journal of Obesity · doi:10.1038/s41366-021-00865-8 · Cited by 16
“post hoc analysis of the LEADER trial cohort exploring neoplasm risk in patients with diabetes mellitus [87], no”
MethodExploring the potential impact of GLP-1 receptor agonists in cancer therapy
Aslam, B., Zafar, M. D. B., Changez, M. I. K., ABDULLAH, M., Safwan, M., QAMAR, B., SHINWARI, A., & Sanjana, R. A. I. (2023) · Minerva Endocrinology · doi:10.23736/s2724-6507.23.04101-5 · Cited by 21
Giorda, C. B., Picariello, R., Tartaglino, B., Nada, E., Costa, G., & Gnavi, R. (2019) · Acta Diabetologica · doi:10.1007/s00592-019-01444-0 · Cited by 15
Incretin‐based drugs and risk of lung cancer among individuals with type 2 diabetes
Rouette, J., Yin, H., Yu, O. H. Y., Bouganim, N., Platt, R. W., & Azoulay, L. (2020) · Diabetic Medicine · doi:10.1111/dme.14287 · Cited by 16
Lu, Y., Dai, H., Tang, H., Donahoo, W. T., George, T. J., Sun, R. C., Jiang, S., Tan, A. C., Guo, Y. M., Licht, J. D., et al. (2025) · Obesity · doi:10.1002/oby.24366 · Cited by 18
“• GLP-1 receptor agonists (GLP-1RAs), originally developed for type 2 diabetes, also promote weight loss and have shown cardiovascular and kidney benefits, but their association with cancer risk remains unclear due to limited and conflicting real-world evidence.”
Ateiwi, Y. A., Mahmood, R. R., Wong, H. J., Low, C. E., Yau, C. E., Lee, A. R. Y. B., Eng, P. C., Lee, M., Chan, M. Y., & Sia, C. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113158 · Cited by 17
Santella, C., Yin, H., Hicks, B. M., Yu, O. H. Y., Bouganim, N., & Azoulay, L. (2020) · Epidemiology · doi:10.1097/ede.0000000000001196 · Cited by 17
“10 This pattern was mirrored in the two observational studies investigating this possible association, 11,12 where GLP-1 RAs appeared to be associated with a transient increased risk of breast cancer between two and three years of use.”
BackgroundResultInfluentialPlaydon, M. C., Hardikar, S. S., Karra, P., Hoobler, R., Ibele, A. R., Cook, K. L., Kumar, A., Ippolito, J. E., & Brown, J. C. (2023) · JNCI Monographs · doi:10.1093/jncimonographs/lgad003 · Cited by 14
“Liraglutide 1.8mg is indicated for treating type 2 diabetes, and an exploratory analysis of the cardiovascular outcome study demonstrated that liraglutide 1.8mg did not increase cancer risk (86).”
BackgroundImproving drug repositioning with negative data labeling using large language models
Picard, M., Leclercq, M., Bodein, A., Scott‐Boyer, M., Périn, O., & Droit, A. (2025) · Journal of Cheminformatics · doi:10.1186/s13321-025-00962-0 · Cited by 12
Lin, Y., Xu, G., Li, L., Xiang, J., & Zhai, L. (2024) · Medicine · doi:10.1097/md.0000000000038018 · Cited by 12
“The 7 articles selected included 2 RCTs [14,15] and 5 cohort studies, [16–20] all of which were population-based studies.”
BackgroundGrandhi, N., Liu, L., Wang, M., Thomas, T. S., Schoen, M. W., Sanfilippo, K. M., Gao, F., Colditz, G. A., Carson, K. R., Janakiram, M., et al. (2024) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkae095 · Cited by 13
Liraglutide Therapy in a Prediabetic State: Rethinking the Evidence
Papaetis, G. S. (2019) · Current Diabetes Reviews · doi:10.2174/1573399816666191230113446 · Cited by 11
A Diabetic Patient Complicated With Pancreatic Cancer After Using Liraglutide: A Case Report
Wu, S., Wang, J., Li, J., & Chen, L. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.608966 · Cited by 10
Liraglutide for the prevention of major adverse cardiovascular events in diabetic patients
Madsbad, S. (2019) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2019.1615444 · Cited by 11
“pancreatic cancer is difficult to obtain because it occurred infrequently [89,90].”
BackgroundThe GLP-1 receptor is expressed in vivo by human metastatic prostate cancer
Stein, M. S., Kalff, V., Williams, S., Murphy, D. G., Colman, P. G., & Hofman, M. S. (2023) · Endocrine Oncology · doi:10.1530/eo-23-0015 · Cited by 15
Ruggiero, R., Longo, M., Mascolo, A., Nuzzo, M. D., Laino, L. V., Caruso, P., D'Amato, R., Rafaniello, C., Maiorino, M. I., Esposito, K., et al. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178004 · Cited by 12
Chou, O. H. I., Lü, L., Chung, C. T., Chan, J. S. K., Chan, R. N. C., Lee, A. Y. H., Dee, E. C., Ng, K., Pui, H. H. H., Lee, S., et al. (2024) · Diabetes & Metabolism · doi:10.1016/j.diabet.2024.101571 · Cited by 11
Hsu, C., Zeng, B., Liang, C., Zeng, B., Hung, C., Stubbs, B., Chen, Y., Lei, W., Chen, J.-J., Chen, P., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178202 · Cited by 12
The emerging role of GLP-1 receptor agonists in treating or preventing cancer
Benjamin, D. J., & Hoff, D. D. V. (2024) · Cancer Drug Resistance · doi:10.20517/cdr.2024.116 · Cited by 9
Beyond Glycemic Control: GLP-1RA–Based Therapies and Emerging Targets Beyond the Metabolic Axis
Matuszewski, W., Wołos-Kłosowicz, K., Włodarczyk, P., Waśniewska, P., Modzelewski, R., Górny, J. M., Szklarz, M., Madeksza, M., & Juranek, J. K. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15072786 · Cited by 5
Krishnan, A., Schneider, C. V., Arkenau, H., Mauro, E., Forner, A., Butsch, W. S., Walsh, D., & Alqahtani, S. A. (2024) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2024.100370 · Cited by 13
“Therefore, many studies have evaluated the association between drug use and overall cancer risk [28].”
BackgroundFang, A. M., Frigo, D. E., Hahn, A. W., Razouki, Z. A., Hwang, J. P., Koutroumpakis, E., Lawen, T., Smith, M. J. S., Hamilton‐Reeves, J. M., DiGiovanni, J., et al. (2025) · Urology · doi:10.1016/j.urology.2025.04.056 · Cited by 5
Nonglycemic Effects of GLP-1 Agonists: From a Starling to Lizards to People
Sood, A., & Swislocki, A. (2019) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2018.0134 · Cited by 4
Acheampong, C. O., Buse, J. B., Klein, K. R., Kim, L. T., Evron, J. M., Kahkoska, A. R., Thompson, C. A., Wang, T., Pate, V., Leese, P., et al. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005090 · Cited by 5
Self-citationEpidemiologia e fatores de risco relacionado a neoplasias pancreáticas: uma revisão da literatura
Mello, D. M. D. S., Neves, V. H. D., Vieira, M. A., Andrade, E. K. B., Martins, T. B. D., & Gomes, I. C. P. (2021) · Revista Eletrônica Acervo Científico · doi:10.25248/reac.e7381.2021 · Cited by 3
The effects and side effects of liraglutide as a treatment for obesity
Ha, J., Yu, J. S., Lee, J., & Kim, H. (2022) · Cardiovascular Prevention and Pharmacotherapy · doi:10.36011/cpp.2022.4.e18 · Cited by 4
Effect of glucagon-like peptide-1 receptor agonists on prostate cancer: A review
Xu, Y., & Liu, J. (2024) · Medicine · doi:10.1097/md.0000000000039956 · Cited by 5
Diabetes Mellitus and the Prostate: The Odd Pairing
Fleifel, M., & Alam, A. E. (2025) · Cureus · doi:10.7759/cureus.90712 · Cited by 3
Zohora, F. T., Mou, S. S., Haque, M. R., Baidya, M., Jahan, I., & Al-Mamun, M. E. (2025) · Translational Medicine of Aging · doi:10.1016/j.tma.2025.08.005 · Cited by 2
Anti-diabetic medications and cancer: links beyond glycemic and body weight control
Cao, M., Lin, C., Cai, X., Lv, F., Yang, W., & Ji, L. (2025) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbaf028 · Cited by 2
“Additionally, a RCT conducted among patients with T2DM showed lowered incidences of prostate cancer in patients treated with liraglutide [ 131 ].”
Chou, O. H. I., Lü, L., Chung, C. T., Chan, J. S. K., Chan, R. N. C., Lee, A. Y. H., Dee, E. C., Ng, K., Pui, H. H. H., Lee, S., et al. (2023) · medRxiv · doi:10.1101/2023.11.25.23298886 · Cited by 3
Wang, Z., Rixiati, Y., Jia, C., Xu, Y., Yin, Z., Huang, J., Dai, J., & Zhang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1434737 · Cited by 3
Sciscent, B. Y., Eberly, H. W., Lorenz, F. J., Goldrich, D. Y., Goyal, N., & Goldenberg, D. (2026) · OTO Open · doi:10.1002/oto2.70188 · Cited by 2
Li, Z., Huang, J., Zhou, S., Luan, Y., Xie, H., Chen, Z., Xu, J., & Qian, J. (2026) · Journal of Diabetes Research · doi:10.1155/jdr/8893769 · Cited by 1
Anderson, B. J., Daele, D. J. V., Claussen, A. D., Tanenbaum, Z. G., & Owen, S. R. (2026) · Annals of Otology Rhinology & Laryngology · doi:10.1177/00034894261450724 · Cited by 1
“78 79-82 A meta-analysis of multiple RCTs and a multi-institution cohort both noted no significant increase in thyroid cancer.”
Metabolic disorders: Sex and gender evidence in dyslipidemia, diabetes, and obesity
Newman, C. B., Saunders, K. H., & Subramanian, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-816569-0.00009-7 · Cited by 1
Lubberding, A. F., Holst, J. J., & Madsbad, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00017-6 · Cited by 1
Scheen, A. J. (2018) · Circulation Research · doi:10.1161/circresaha.118.313485
Thérapeutique des désordres glycémiques
(2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75889-8.00007-5
Onkodiabetológia II. Antidiabetikumok és rákmegelőzés
Bánhegyi, R. J., Gazdag, A., Rácz, B., Szalai, L., Wagner, R. J., & Fülöp, N. (2022) · Orvosi Hetilap · doi:10.1556/650.2022.32041 · Cited by 2
János, B. R. (2023) · Pesci Egyetemi Archivum (University of Pécs) · doi:10.15170/pte.2023.004
Chou, O. H. I., Lü, L., Yang, Y., Chung, C. T., Chan, J., Chan, R. N. C., Lee, A. Y. H., Dee, E. C., Ng, K., Pui, H. H. H., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4765231
Shen, L., Yang, Y., Lü, L., Chou, O. H. I., Lee, Q., Liu, T., Li, G., Cheng, S. H., Tse, G., & Zhou, J. (2024) · medRxiv · doi:10.1101/2024.09.15.24313695 · Cited by 1
Serum fatty acid synthase and GLP-1 levels in prostate cancer and benign prostatic hyperplasia
Üner, A., Noyan, T., & Benli̇, E. (2025) · Turkish Journal of Biochemistry · doi:10.1515/tjb-2025-0254
“Available evidence indicates that GLP-1 agonists might be advantageous in the management of prostate cancer [24].”
Khawandanah, D. O., Alyamani, F. F., Almutairi, B. R., Almutairi, B. A., Alharbi, R. M., Alghanmi, S., Alsouri, M. T., & ALMUTAIRI, A. R. (2025) · Saudi Journal of Clinical Pharmacy · doi:10.4103/sjcp.sjcp_22_25 · Cited by 1
Metabolic disorders: Sex and gender evidence in dyslipidemia, diabetes, and obesity
Newman, C. B., Saunders, K. H., Schmitz, S. H., & Subramanian, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-26712-3.00020-3
Glucagon-like Peptide-1 Receptor Agonists and Colorectal Cancer Risk
WINKELMAN, J. E., & LeVine, M. J. (2026) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2026.02.013
“It followed 9340 adults with T2DM and high cardiovascular risk over a median of 3.8 years, and demonstrated no significant difference in malignant or CRC incidence between liraglutide and placebo groups (hazard ratio [HR] 1.06, 95% CI 0.90 — 1.25) 39 .”
InfluentialWang, Q., Xu, J., Liu, Q., Zhou, H., & Hu, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1805197
Kazi, M. A. I., Khan, J., Mufarrih, S. M., Siddiqui, M., Ansari, H. U. H., Ahmed, M., Qureshi, I., Al-Sabban, A. M., Karnik, N. P., Gilman, A. J., et al. (2026) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-026-01523-w
Type 2 diabetes medications and their implications for cancer treatment: A comprehensive review
Shakour, N., Hosseini, F., Esmaeili, Z., & Hadizadeh, F. (2026) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2026.101521
Metadata
- Authors
- Nauck, M. A., Jensen, T. J., Rosenkilde, C., Calanna, S., Buse, J. B., & the LEADER Publication Committee on behalf of the LEADER Trial Investigators
- Affiliations
- St. Josef-Hospital (DE)
- Novo Nordisk (Denmark) (DK)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Nauck, Michael A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-06-13
- Volume
- 41
- Issue
- 8
- Pages
- 1663-1671
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC6463597
- OpenAlex
- W2807726778
- Semantic Scholar
- caf4b597cece1cdf24ad7c1a0f9d0f159ed8fa2c
- Cited by
- 94
- References
- 38
- Citations by year
- 2026: 10 · 2025: 14 · 2024: 15 · 2023: 14 · 2022: 8 · 2021: 14 · 2020: 9 · 2019: 6 · 2018: 4
- FWCI
- 6.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (UL1TR001111)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- liraglutide, type 2 diabetes, cancer, benign tumors, GLP-1 receptor agonists, pancreatic cancer, thyroid cancer, prostate neoplasms, drug safety, LEADER trial
- MeSH terms
- Liraglutide, Adult, Aged, Aged, 80 and over, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypoglycemic Agents, Male, Middle Aged, Neoplasms, Placebos, Risk Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.